Financial statements Europharma Research & Science Center

Balance sheet of Europharma Research & Science Center

Company age:
Age:
18 y. 8 m. 24 d.
Share capital:
Share capital:
50 000 PLN

Balance sheet data of EUROPHARMA RESEARCH & SCIENCE CENTER

Year
2018
2019
2020
2021
2022
2023
Total assets 5 625 168,58 5 294 721,72 4 275 781,05 5 283 392,96 4 098 546,12 3 870 390,85
A. Fixed assets 816 036,45 710 619,86 1 226 328,56 1 627 548,12 1 772 158,96 1 793 062,80
B. Current assets 4 809 132,13 4 584 101,86 3 049 452,49 3 655 844,84 2 326 387,16 2 077 328,05
C. Share capital contributions (basic funds) 0,00 0,00 0,00 0,00 0,00 0,00
D. Own shares (stocks) 0,00 0,00 0,00 0,00 0,00 0,00
Total liabilities 5 625 168,58 5 294 721,72 4 275 781,05 5 283 392,96 4 098 546,12 3 870 390,85
A. Equity 2 790 125,72 3 349 551,63 1 042 181,89 1 885 286,50 2 467 486,25 2 915 917,18
B. Liabilities and provisions for liabilities 2 835 042,86 1 945 170,09 3 233 599,16 3 398 106,46 1 631 059,87 954 473,67
I. Long-term liabilities 0,00 0,00 866 110,50 72 175,86 0,00 0,00
II. Short-term liabilities 2 810 841,01 1 921 796,24 2 364 176,66 3 323 446,60 1 629 403,87 953 645,67
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.

  • Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
  • Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
  • Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
  • Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
  • Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
  • Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.